710.3000 0.45 (0.06%)
NSE Jul 14, 2025 15:31 PM
Volume: 588.7K
 

ICICI Securities Limited
Krishna Institute of Medical Sciences’ (KIMS) Q1FY24 sequential revenue growth of 5.2% was mainly driven by ARPOB improvement of 3.7% while occupancy and OPD consultations were largely flat. As guided by the management, Telangana belt margin normalised to ~31% due to surge in overheads and seasonality while addition of gastro unit in Andhra Pradesh (AP) dented margins of that belt.
Prabhudas Lilladhar released a Buy report for Krishna Institute of Medical Sciences Ltd. with a price target of 725.0 on 30 Jun, 2025.
More from Krishna Institute of Medical Sciences Ltd.
Recommended